N/A N=67 Tanglewood to Table: A Walking Farmer's Market Group and Control
Dietary Habits
Primary: Fruit Intake — 2.5; 2.9; 2.3; 1.9 servings of fruit per day
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=344 A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Lewy Body Dementia
Primary: Change From Baseline in the Continuity of Attention (CoA) Composite Score of the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB) — 1.04; 0.15; 0.96…
Phase 2 N=63 An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults
Healthy
Primary: Area Under the Viral Load-Time Curve (VL-AUC) of Respiratory Syncytial Virus (RSV) by Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) — 0; 236…
N/A N=56 The Articulated Oral Airway as an Aid to Mask Ventilation
Mask Ventilation · Airway Obstruction Upper · Airway Management
Primary: Expiratory Tidal Volume (Breaths 6-10) — 4.46; 3.21; 3.12; 3.48 ml/kg
Phase 4 N=1,062 Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
Relapsing Remitting Multiple Sclerosis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs) — 204; 500; 879; 55 Participants
N/A N=275 Improving Diabetes Care Through Effective Personalized Patient Portal Interactions
Diabetes Mellitus
Primary: Any My HealtheVet Patient Portal Use — 6; 1; 5; 8 Participants — p=0.057
Phase 2 N=105 A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread
Advanced Cancer
Primary: Number of Participants With Adverse Events (AEs) — 41; 21; 42 Participants
Phase 2 N=166 Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
Pulmonary Arterial Hypertension · Pulmonary Hypertension · Interstitial Lung Disease
Primary: Change From Baseline Though Week 16 in 6-Minute Walk Distance (6MWD) for Bardoxolone Methyl Compared to Placebo — 32.5; 24; 3.4; -3.2 meters — p=0.8133
Phase 1 N=32 A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430
Marburg Virus Disease
Primary: Galidesivir Safety and Tolerability, as Measured by the Number of Participants Experiencing Adverse Events. — 2; 0; 1; 4 participants
Phase 1 N=144 A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)
Autism Spectrum Disorder
Primary: Children's Yale-Brown Obsessive Compulsive Scale Modified for Autism Spectrum Disorder (CY-BOCS-ASD) - Total Score — 14.81; 14.60; 14.94; 15.71 Score on a Scale
Phase 4 N=15 TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment
Clostridium Difficile Infection · Diarrhea
Primary: Number of Participants With Detectable C. Difficile — 5; 4 Participants
N/A N=22 Randomized Crossover of NAVA and Synchronized Intermittent Pressure Ventilation in Neonates and Infants
Respiratory Insufficiency · Infant, Newborn, Disease
Primary: Respiratory Severity Score (MAP X FiO2) — 3.83; 3.82; 3.46; 3.86 score on a scale
N/A N=7,899 Integrating Use of Self-Affirmation Content Into a Mobile App to Promote Quit Attempts With Text-Based Smoking Cessation Intervention Messaging
Number of Quit Attempts
Primary: Number of Participants Reporting a Quit Attempt Within the Past Week at 1 Month and 3 Months — 142; 143; 139; 145 Participants
Phase 3 N=84 Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
Moderate to Severe Chronic Plaque-type Psoriasis
Primary: Number and Percentage of Participants With PASI 75 Response — 39; 39 Participants
Phase 2 N=25 Treatment of Primary Liver Tumors With Electrochemotherapy (ECT)
Liver Cancer
Primary: Number of Participants With Toxicity Related to Electrochemotherapy — 20; 0; 0; 4 Participants